PDF icon Download PDF
Open Access
CC BY 4.0 · Journal of Coloproctology 2024; 44(S 01): S1-S138
DOI: 10.1055/s-0045-1808709
Doença Inflamatória Intestinal
Inflammatory Bowel Disease
ID – 141700
E-poster

BACTERIOPHAGES IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Matheus Amorim Grigorio
1   Centro Universitário do Planalto Central Apparecido dos Santos, Brasília, Brasil
,
Raphael Vinicius Mendes Abreu
1   Centro Universitário do Planalto Central Apparecido dos Santos, Brasília, Brasil
,
Sacha da Silva Faria
2   Universidade Evangélica de Goiás, Anápolis, Brasil
,
Luiza Camapum Fernandes Ribeiro
2   Universidade Evangélica de Goiás, Anápolis, Brasil
,
Ana Julia Faria Ramos
3   IMEPAC, Araguari, Brasil
,
Lucas Adati Taira
1   Centro Universitário do Planalto Central Apparecido dos Santos, Brasília, Brasil
,
Leandro Adati Taira
4   Centro Universitário Presidente Antônio Carlos, Juiz de Fora, Brasil
,
Eduardo Henrique Lacoski Santos
5   Pontifícia Universidade Católica, Curitiba, Brasil
› Author Affiliations
› Further Information
Also available ateRef
 
 PDF Download Permissions and Reprints

    Introduction Inflammatory Bowel Disease (IBD) is a chronic condition with increasing incidence, caused by the interaction of environmental, genetic, and immunological factors, resulting in persistent inflammation in the intestine. Intestinal dysbiosis, an imbalance in the microbiota, is frequently associated with the development and worsening of IBD symptoms. Current therapies, such as aminosalicylates and immunosuppressants, may have side effects and are not always effective for all patients.

    Objective This scoping review aims to summarize scientific evidence on the use of bacteriophages, viruses that infect specific bacteria, as a promising therapeutic alternative in the treatment of IBD.

    Methodology A scoping review was conducted to map and summarize the existing knowledge on the use of bacteriophages in IBD. The search covered the SciELO and PubMed databases, using the descriptors “bacteriophage” and “inflammatory bowel disease” in combination with the Boolean operator “AND.” The search period covered 2018 to 2023, including articles published in Portuguese and English. The selection of studies was based on relevance to the topic and methodological quality, prioritizing original articles, systematic reviews, and case studies.

    Discussion The research revealed the potential of bacteriophages in controlling intestinal dysbiosis, modulating the microbiota, and reducing inflammation. The ability of bacteriophages to target drug-resistant bacteria makes them an attractive alternative in the context of increasing antimicrobial resistance. Additionally, bacteriophage therapy appears to be a personalized and controlled option, with promising results in preliminary studies. The safety and efficacy of bacteriophages have been demonstrated in various areas, such as food safety and animal health, reinforcing their therapeutic potential in IBD.

    Conclusion The use of bacteriophages in the treatment of IBD emerges as a promising alternative, with the potential to control intestinal dysbiosis, reduce inflammation, and improve patients' quality of life. Continued research in this area is essential to establish effective and safe treatment protocols, opening new perspectives for IBD management.


     

    No conflict of interest has been declared by the author(s).

    Publication History

    Article published online:
    25 April 2025

    © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

    Thieme Revinter Publicações Ltda.
    Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

      Permissions and Reprints